A 45% heart function means an ejection fraction of 45%, which is mildly reduced. Each beat, your left ventricle pumps out 45% of the blood it holds, against a normal of 55% to 70%. Per the 2022 AHA/ACC/HFSA heart failure guideline, 41% to 49% defines heart failure with mildly reduced ejection fraction, or HFmrEF. It is not normal, and it is not severe. Most people at 45% live for years with breathlessness on exertion, daily medications, and structured monitoring. Untreated, the same number carries a five-year mortality near 50%, so the diagnosis changes everything.
What the 45% Number Actually Measures
Ejection fraction is a ratio, not a flow rate. It divides stroke volume, the blood ejected per beat, by end-diastolic volume, the blood in the ventricle just before contraction. A healthy 70 mL stroke volume from a 120 mL filled ventricle gives an ejection fraction of about 58%.
The critical point is that a normal ejection fraction does not guarantee normal pumping. Concentric hypertrophy, common in long-standing hypertension, thickens the wall so the chamber holds less blood. Stroke volume can fall while the percentage stays at 60%. This is heart failure with preserved ejection fraction, and it affects roughly half of all heart failure patients.
Ejection fraction also assumes a geometrically uniform ventricle. In dilated cardiomyopathy the chamber becomes spherical, and two-dimensional estimates can drift 5 to 10 points from cardiac MRI, which is the reference standard. A 45% on echocardiography may read 40% or 50% on MRI. In plain terms: the percentage is a useful shorthand, not a direct measurement of how hard your heart works.
The Measured Spectrum: Where 45% Sits
The 2022 guideline created the 41% to 49% band specifically to end a contradiction. Before it, trials excluded these patients, so clinicians guessed. The band now has its own label, HFmrEF, and its own logic: many patients improve past 50% or decline below 40%, so the category is a snapshot, not a permanent address.
| Ejection Fraction | Category | Approximate Annual Mortality | Typical Strategy |
|---|---|---|---|
| 70% or higher | Normal to hyperdynamic | Under 1% | Treat the cause |
| 55% to 69% | Normal | About 1% to 2% | Risk factor control |
| 50% to 54% | Low normal, borderline | About 2% to 3% | Monitor, treat comorbidities |
| 41% to 49% | Mildly reduced (HFmrEF) | About 5% to 7% | Four-drug therapy, reassess at 3 months |
| 30% to 40% | Reduced (HFrEF) | About 8% to 10% | Full guideline therapy, device evaluation |
| Under 30% | Severely reduced | 15% or higher | ICD, advanced therapy referral |
The 50% and 40% thresholds are the two that change management. Crossing 50% upward usually means recovery and possible medication de-escalation. Crossing 40% downward unlocks implantable defibrillator criteria.
How 45% Compares With Normal and Reduced Function
The practical difference between 45% and 30% is not just 15 points. It is a difference in stroke volume of roughly 25 to 35 mL per beat at rest, and far more during exercise. A person at 45% can usually climb one flight of stairs; a person at 30% often cannot without stopping.
The difference between 45% and 60% is subtler and more deceptive. At rest, cardiac output is often maintained because the body raises heart rate and narrows blood vessels to compensate. The deficit appears only under load. This is why a resting echocardiogram at 45% can look reassuring while a six-minute walk test or cardiopulmonary exercise test exposes a peak oxygen consumption 20% to 30% below predicted.
The quantified comparison most sources miss: exercise capacity at 45% correlates more strongly with peak oxygen uptake than with the ejection fraction itself. Two patients at 45% can differ by 10 mL/kg/min in peak oxygen consumption, which is the difference between mild and marked limitation. Per the 2018 ACC/AHA cardiopulmonary exercise testing guideline, peak oxygen uptake below 14 mL/kg/min supports transplant evaluation. Ejection fraction alone does not.
What Causes Function to Sit at 45%
The mechanism differs by cause, and the cause determines the trajectory. Ischemic cardiomyopathy, from prior heart attack, kills muscle and replaces it with scar that does not contract; a single large anterior infarct can drop function to 45% within days. Non-ischemic dilated cardiomyopathy stretches the chamber over months to years, often after a viral illness or with no identified trigger.
Tachycardia-mediated cardiomyopathy is the reversible edge case. Sustained fast rates above 100 to 110 beats per minute for weeks can depress function to 45% or lower. Restore sinus rhythm and function often recovers to normal within four to eight weeks. This is why rate control is a first step, not an afterthought.
Chemotherapy-related cardiotoxicity is the other non-obvious cause. Anthracyclines and HER2-targeted therapies can drop function by 10 points or more. Per the 2022 ESC cardio-oncology guideline, a decline to below 50% with a 10-point drop from baseline triggers cardioprotective therapy, even when the absolute number remains above 40%.
The Timeline From Diagnosis to Stability
Function at 45% moves on two clocks: the short clock of the first three months, when guideline therapy remodels the ventricle, and the long clock of years, when the underlying cause evolves. Both matter for planning.
| Time From Diagnosis | What Happens | Typical Action |
|---|---|---|
| Day 0 to 7 | Baseline echo, labs, ECG, cause workup | Start ARNI or ACE inhibitor, beta-blocker |
| Week 2 to 4 | Blood pressure and renal function check | Titrate medications, start MRA |
| Month 3 | Repeat echo | Assess response; add SGLT2 inhibitor |
| Month 3 to 6 | Device evaluation if ejection fraction remains 35% or lower | ICD discussion |
| Month 6 to 12 | First stable reassessment | Titrate to target doses |
| Year 1 to 3 | Risk of progression or recovery | Yearly echo, symptom review |
| Year 3 to 5 | Long-term trajectory visible | Adjust to function trend |
Function that improves by 10 points or more by month three, and holds there by month twelve, carries a substantially better prognosis. Recovery of 10 or more points, called reverse remodeling, occurs in roughly 20% to 40% of patients on modern four-drug therapy.
Four-Drug Therapy and the 45% Threshold
The medication stack for 41% to 49% mirrors the reduced-function stack: an ARNI (sacubitril-valsartan) or ACE inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. The evidence is strongest for SGLT2 inhibitors, which per the 2021 EMPEROR-Preserved trial reduced heart failure hospitalization across the 40% to 60% range. Effect sizes in the 41% to 49% band are smaller than at 30%, roughly a 20% relative risk reduction in hospitalization versus 25% to 30% below 40%.
Of roughly 1,000 patients treated for one year, about 40 to 60 avoid a hospitalization at 41% to 49%. The same 1,000 at 30% avoid 70 to 90. The lower the number, the more each prescription earns. At 45%, adherence and titration still matter, but the marginal benefit per drug is smaller.
This is also why some clinicians de-escalate after recovery. A patient who reaches 50% on four drugs may be able to hold with two, though the 2022 guideline advises caution and ongoing monitoring rather than routine withdrawal.
Red Flags That Change the Plan at 45%
A stable 45% needs outpatient management. The following symptoms need same-day contact or emergency care, because they signal decompensation beyond what the number alone predicts:
- New breathlessness at rest, or breathlessness that wakes you from sleep
- Weight gain of 2 to 3 pounds in one day, or 5 pounds in one week
- Swelling in the ankles, legs, or abdomen that worsens over days
- Fainting, near-fainting, or sustained palpitations
- Chest pain with exertion that is new or worsening
- Inability to lie flat without propping up on pillows
Weight monitoring belongs in the plan, not the background. Daily weights are the cheapest early warning available.
Limits of the 45% Figure
The number is a snapshot of one chamber at one moment. It ignores right ventricular function, which independently predicts survival. It ignores the left atrium, whose dilation signals chronic pressure. It ignores valve disease, pulmonary pressures, and the patient's own symptom burden.
Two patients at 45% can have genuinely different diseases. A 38-year-old with a viral cardiomyopathy has a recovery trajectory measured in months. An 82-year-old with ischemic scar and chronic kidney disease has a trajectory measured in years of managed decline. The same number, the same guideline band, different plans.
Hypothesis, not established science: the specific mechanisms that drive reverse remodeling in some patients and not others remain partially characterized. Research points to changes in myocyte calcium handling and the extracellular matrix, but no marker reliably predicts who recovers past 50%.
What to Actually Do at 45%
Start with the numbers you control. Daily weights, blood pressure logs, and a symptom diary three times a week make the next clinic visit more useful than any single test.
Ask for a repeat echocardiogram at three months. The first scan set the baseline; the second scan tells you whether the plan is working. A decline to 40% or below changes eligibility for devices.
Ask explicitly about all four drug classes. Some clinics still prescribe two and stop. The 2022 guideline recommendation is for all four unless contraindicated, and the 45% band is included.
Ask about exercise. Supervised cardiac rehabilitation improves peak oxygen consumption by 15% to 20% in the 40% to 50% range, independent of ejection fraction change. In plain terms: fitness can improve without the number moving.
Ask about cause, not just category. A reversible trigger, such as rapid heart rate, alcohol, or a thyroid problem, changes everything. If no trigger is found, that is itself useful information.
Reconcile the numbers you are given in one place. A resting ejection fraction of 45%, a peak oxygen uptake of 18 mL/kg/min, and a six-minute walk of 400 meters tell a more complete story than any single figure, and no two of them should contradict without explanation.